This FAQ summarizes a Special Report discussion on how two experts decide who is a candidate for testosterone therapy in women, from symptoms and context to hormone state vs age.
|Videos|March 15, 2021
The Management of Chronic Gynecologic Conditions During COVID and Beyond
Experts discuss management of women’s health including chronic pelvic pain resulting from endometriosis and heavy menstrual bleeding from uterine fibroids. They also discuss ways to help improve patient-provider communications and overcome the normalization associated with non-malignant gynecological conditions.
Advertisement
ABBV-US-00348-MC v1.0 Approved 04/2021
Advertisement
Related to this article
This FAQ summarizes a Special Report discussion of what the evidence does and does not establish about testosterone therapy in women.
Kanchi Chadha, MD, FACOG, MSCP, supports reconsidering MHT boxed warnings but says the FDA cited no study behind the change.
HRSA will award up to $1 million to a single organization to update the Women's Preventive Services Guidelines through the new WISH program.
Real-world data show maternal RSVpreF vaccination was 82% effective against infant RSV LRTI hospitalization through 3 months.
Soma Mandal, MD, MSCP, says removing MHT boxed warnings is overdue but calls for transparency on the FDA's product-specific rationale.
CMS' proposed G-codes, which experts stated would cause confusion in combination with the AMA's proposed codes, were not included in the final fee schedule for 2027, according to ACOG.
Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Centers for Medicare, Medicaid Services includes AMA's obstetric codes in 2027 fee schedule
2
FAQ: Who is a candidate for testosterone therapy in women?
3
FAQ: What does the evidence show about testosterone in women?
4
Q&A: Kanchi Chadha, MD, FACOG, MSCP, on FDA boxed warning removals
5